The differential findings for PFS based on sMSLN levels with anti-MSLN therapy compared to anti-PD1 therapy, in addition to the findings reported herein, indicate that sMSLN binds to and sequesters the MSLN antibody-based therapies before reaching the tumor surface10. Here, MSLN is linked to neoplasm.